Literature DB >> 30020025

A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.

Alan K Davis1, Elise Renn2, Austin-Marley Windham-Herman2,3, Martin Polanco2, Joseph P Barsuglia2.   

Abstract

We examined persisting effects, self-perceived challenges, and potential benefits associated with positive outcomes following ibogaine detoxification using data collected as part of a larger online retrospective study of 73 patients who received treatment for chronic opioid use in Mexico between 2012 and 2015. A mixed-methods design was used comparing treatment responders versus non-responders, as well as content coding of themes from open-ended questions. Most participants reported positive persisting effects of ibogaine detoxification (e.g., enhanced personal sense of gratitude and authenticity, and meaning and appreciation for life). Compared to non-responders, treatment responders endorsed greater persisting changes in their ability to tolerate difficult/painful feelings, capacity for coping with stress, and reduced unhealthy anger. Treatment responders reported greater change in subjective levels of inner peace, joy, feelings of love/openheartedness, and experiences of sacredness in life. Qualitative analyses revealed that treatment responders reported a heightened sense of spiritual awareness and greater connection to their intra-/interpersonal relationships after ibogaine detoxification. Notable challenges of ibogaine detoxification included psychological and health-related difficulties during treatment and challenges with post-treatment integration. Findings highlight the persisting effects associated with positive response to ibogaine detoxification and possible post-treatment needs (i.e., more integration/aftercare resources). Future research using rigorous experimental designs is needed.

Entities:  

Keywords:  Ibogaine; heroin; persisting effects; prescription opioids

Mesh:

Substances:

Year:  2018        PMID: 30020025      PMCID: PMC6247813          DOI: 10.1080/02791072.2018.1487607

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  29 in total

1.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

2.  Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.

Authors:  Geoffrey E Noller; Chris M Frampton; Berra Yazar-Klosinski
Journal:  Am J Drug Alcohol Abuse       Date:  2017-04-12       Impact factor: 3.829

3.  Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences.

Authors:  Annamarie Heink; Steve Katsikas; Tiffany Lange-Altman
Journal:  J Psychoactive Drugs       Date:  2017-03-07

4.  Treatment of acute opioid withdrawal with ibogaine.

Authors:  K R Alper; H S Lotsof; G M Frenken; D J Luciano; J Bastiaans
Journal:  Am J Addict       Date:  1999

5.  Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.

Authors:  Erich Studerus; Michael Kometer; Felix Hasler; Franz X Vollenweider
Journal:  J Psychopharmacol       Date:  2010-09-20       Impact factor: 4.153

6.  Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.

Authors:  Thomas Kingsley Brown; Kenneth Alper
Journal:  Am J Drug Alcohol Abuse       Date:  2017-05-25       Impact factor: 3.829

7.  Alterations in brain structure and functional connectivity in prescription opioid-dependent patients.

Authors:  Jaymin Upadhyay; Nasim Maleki; Jennifer Potter; Igor Elman; David Rudrauf; Jaime Knudsen; Diana Wallin; Gautam Pendse; Leah McDonald; Margaret Griffin; Julie Anderson; Lauren Nutile; Perry Renshaw; Roger Weiss; Lino Becerra; David Borsook
Journal:  Brain       Date:  2010-06-16       Impact factor: 13.501

Review 8.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 9.  Opioid agonist treatment for pharmaceutical opioid dependent people.

Authors:  Suzanne Nielsen; Briony Larance; Louisa Degenhardt; Linda Gowing; Chyanne Kehler; Nicholas Lintzeris
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

10.  Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning.

Authors:  Alan K Davis; Joseph P Barsuglia; Austin-Marley Windham-Herman; Marta Lynch; Martin Polanco
Journal:  J Psychedelic Stud       Date:  2017-10-17
View more
  1 in total

1.  Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.

Authors:  Margarida L F Martins; Paniz Heydari; Wenlong Li; Alejandra Martínez-Chávez; Nikkie Venekamp; Maria C Lebre; Luc Lucas; Jos H Beijnen; Alfred H Schinkel
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.